Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 12% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Buntanetap tartrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Buntanetap tartrate overview

Buntanetap (ANVS-401 (Posiphen)) is under development for the treatment of Alzheimer's disease, Parkinson's disease, Alzheimer's disease in Down syndrome , frontotemporal dementia (FTD), chronic traumatic encephalopathy (CTE) and Lewy body dementia. The drug candidate is the enantiomer of phenserine. It is administered through oral route. It acts by targeting amyloid precursor protein (APP), tau and alpha-synuclein.

It was also under development for the treatment of Huntington’s disease and traumatic brain injury. 

Annovis Bio overview

Annovis Bio is a clinical-stage drug platform company that carries out the development of novel drugs for the treatment of various diseases. The company’s pipeline products comprise buntanetap, to treat Parkinson’s disease (PD), Alzheimer’s disease (AD), and other chronic neurodegenerative diseases; ANVS405, to treat traumatic brain injury (TBI) and stroke; ANVS301, to treat advanced Alzheimer’s disease. It provides drug candidates in oral and injectable forms. Annovis Bio also carries out preclinical animal studies and clinical trials. The company collaborates with contractor laboratories, independent contractors and contract research organizations. Annovis Bio is headquartered in Berwyn, Pennsylvania, the US.

For a complete picture of Buntanetap tartrate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.